Jump to content

The Combat Methamphetamine Epidemic Act of 2005

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Miserlou (talk | contribs) at 20:12, 1 January 2007 (Started!). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

The Combat Methamphetamine Epidemic Act of 2005 (CMEA) was signed into United States law on March 9, 2006 to regulate, among other things, retail over-the-counter sales of ephedrine, pseudoephedrine, and phenylpropanolamine products. Retail provisions of the CMEA include daily sales limits and 30-day purchase limits, placement of product out of direct customer access, sales logbooks, customer ID verification, employee training, and self-certification of regulated sellers. The CMEA is found as Title VII of the USA PATRIOT Improvement and Reauthorization Act of 2005.[1]

Reason

Ephedrine, pseudoephedrine, and phenylpropanolamine are precursor chemicals used in the illicit manufacture of methamphetamine or amphetamine. They are also common ingredients used to make cough, cold, and allergy products. Passage of the CMEA was accomplished to curtail the clandestine production of methamphetamine. States that have enacted similar or more restrictive retail regulations have seen a dramatic drop in small clandestine labs.[2]

References

  1. ^ DEA (01-01-07). "CMEA Q and A". {{cite web}}: Check date values in: |date= (help)
  2. ^ DEA (01-01-07). "CMEA Q and A". {{cite web}}: Check date values in: |date= (help)

Sources